On 06 October 2021, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency published an update on the safety of COVID-19 vaccines, based on the evaluation of safety reports received from around the world. Spontaneously reported cases concern adverse events observed after vaccination but not necessarily related to it.
Vaxzevria (AstraZeneca)
Thrombocytopenia, including immune thrombocytopenia
Update of the instructions for medical use
PRAC completed its evaluation of cases of thrombocytopenia, including immune thrombocytopenia (ITP), after vaccination with Vaxzevria and recommended updating the instructions for medical use by including ITP with the frequency “Not known” in the section “Adverse reactions”.
Comirnaty and Spikevax
Erythema multiforme
Update of the instructions for medical use
PRAC continued its assessment of whether erythema multiforme may be an adverse reaction following vaccination with Comirnaty and Spikevax. Based on the assessment of reports with a close temporal association and the absence of alternative causes of erythema multiforme, PRAC concluded that the adverse reaction “erythema multiforme” with the frequency “Not known” should be included in the “Adverse reactions” section of the package inserts.
Menstrual cycle disorders
No causal relationship has been established.
PRAC assessed cases of menstrual cycle disorders reported after vaccination.
Based on the assessment of all data, PRAC concluded that there is currently no evidence of a causal relationship between menstrual cycle disorders and vaccination.
Glomerulonephritis and nephrotic syndrome
Assessment ongoing
PRAC evaluated reports of glomerulonephritis and nephrotic syndrome after vaccination
PRAC concluded that, based on the available data, a causal relationship between the development of glomerulonephritis and nephrotic syndrome and the use of vaccines cannot be established, and a corresponding update of the package inserts is currently not warranted. PRAC urges all healthcare professionals and patients to report any cases of glomerulonephritis and nephrotic syndrome in vaccinated persons.
Comirnaty
Paresthesias and hypoesthesias
Update of the instructions for medical use
The PRAC concluded that paresthesia and hypoesthesia should be added to the “Adverse reactions” section of the instructions for medical use.
Other events: asthenia, lethargy, decreased appetite, and (night) hyperhidrosis
Update of the instructions for medical use
In view of clinical study data, the Committee for Medicinal Products for Human Use (CHMP) recommended adding asthenia, lethargy, decreased appetite, and (night) hyperhidrosis with the frequency “Uncommon” to the section “Adverse reactions” of the instructions for medical use
Janssen
Venous thromboembolism (VTE)
Update of the instructions for medical use
The PRAC evaluated the clinical study data and, taking all the evidence into account, concluded that there is a reasonable possibility that VTE is associated with vaccination. Therefore, the PRAC recommends adding VTE to the instructions for medical use of the vaccine with the frequency “Rare”.
Immune thrombocytopenia
Update of the instructions for medical use
In August 2021, the instructions for medical use were updated – the adverse reaction “Immune thrombocytopenia” was added.
At the meeting held on 27-30 September 2021, the PRAC decided to add the frequency “Not known” for the adverse reaction “Immune thrombocytopenia”.
Thrombosis with thrombocytopenia syndrome (TTS)
Update of the instructions for medical use
In May 2021, the instructions for medical use were updated by adding thrombosis with thrombocytopenia syndrome with the frequency "Very rare" to the section "Adverse reactions".
Cases of thrombosis with thrombocytopenia syndrome are under close monitoring. Based on updated data, PRAC concluded that the current information stating that TTS cases occurred mainly in women should be removed from the instructions for medical use (currently no sex imbalance is observed).
Transverse myelitis
Update of the instructions for medical use
PRAC recommended including the adverse reaction “Transverse myelitis” in the package insert for medical use as an adverse reaction with the frequency “Not known.”
Dizziness
Update of the instructions for medical use
In August 2021, PRAC recommended adding the adverse reaction “Dizziness” to the package insert. The frequency has now been defined as “Uncommon”.
The original text of the publication can be found at the links: